In Q4, focus remains on prudent guidance due to market challenges, but potential upside exists if Q4 execution surpasses expectations. Priority on high ROI projects and funding boosts confidence for 2025. Strong uptake in biologics and cell and gene therapies with sterility reinforcing growth.